Transforming Community-Based Healthcare

Corporate Presentation

April 2021



Safe Harbor and Disclaimer

This presentation (together with oral statements made in connection herewith, this "Presentation") is provided for informational purposes only and has been prepared to assist interested parties in making their own evaluation with respect to a potential business combination between LumiraDx Limited ("LumiraDx") and CA Healthcare Acquisition Corp. ("CAH") and related transactions (the "Proposed Business Combination") and for no other purpose.

No representations or warranties, express or implied are given in, or in respect of, this Presentation. To the fullest extent permitted by law, in no circumstances will CAH, LumiraDx or any of their respective subsidiaries, stockholders, affiliates, representatives, partners, directors, officers, employees, advisers or agents be responsible or liable for any direct, indirect or consequential loss or loss of profit arising from the use of this Presentation, its contents, its omissions, reliance on the information contained within it, or on opinions communicated in relation thereto or otherwise arising in connection therewith. In addition, this Presentation does not purport to be all-inclusive or to contain all of the information that may be required to make a full analysis of LumiraDx or the Proposed Business Combination. Viewers of this Presentation should each make their own evaluation of LumiraDx and of the relevance and adequacy of the information and should make such other investigations as they deem necessary. Nothing herein should be construed as legal, financial, tax or other advice. You should consult your own advisers concerning any legal, financial, tax or other considerations concerning the opportunity described herein. The general explanations included in this Presentation cannot address, and are not intended to address, your specific investment objectives, financial situations or financial needs.

The proposed business combination will be submitted to the stockholders of CAH for their consideration and approval at a special meeting of stockholders. LumiraDx intends to file a registration statement on Form F-4 (the "Registration Statement") with the SEC, which will include preliminary and definitive proxy statements and be distributed to holders of CAH's common stock in connection with CAH's solicitation for proxies for the vote by CAH's stockholders in connection with the proposed business combination and other matters as described in the Registration Statement, as well as the prospectus relating to the offer of the securities to the issued to CAH's shareholders in connection with the completion of the business combination. After the Registration Statement has been filed and declared effective, CAH will mail a definitive e proxy statement and other relevant documents to its stockholders as of the record date established for voting on the proposed business combination. CAH's stockholders and other interested parties are advised to read, once available, the preliminary proxy statement and any amendments thereto and, once available, the definition proxy statement / prospectus, in connection with CAH's solicitation of proxies for its special meeting of stockholders to be held to approve, among other things, the proposed business combination, because these documents will contain important information about CAH, LumiraDx and the proposed business combination. Stockholders may also obtain a copy of the preliminary or definitive proxy statement / prospectus, once available, as well as other documents filed with the SEC regarding the proposed business combination and other documents filed with the SEC by CAH, without charge, at the SEC's website located at www.sec.gov or by directing a request to 99 Summer Street, Suite 200, Boston, MA 02110, Attention: [name of CAH contact] ([email address]). This Presentation does not constitute a solicitation of any a proxy.

CAH and its directors and executive officers and other persons may be deemed to be participants in the solicitations of proxies from CAH's stockholders in respect of the Proposed Business Combination and the other matters set forth in the definitive proxy statement / prospectus. Information regarding CAH's directors and executive officers is available under the heading "Management" in CAH's final prospectus dated January 26, 2021. Additional information regarding the participants in the proxy solicitation and a description of their direct and indirect interests, by security holdings or otherwise, will be contained in the proxy statement / prospectus relating to the Proposed Business Combination when it becomes available. Stockholders, potential investors and other interested persons should read the proxy statement / prospectus carefully when it becomes available.

FORWARD-LOOKING STATEMENTS

All statements other than statements of historical facts contained in this Presentation are forward-looking statements. Forward-looking statements may generally be identified by the use of words such as "believe," "may," "will," "estimate," "continue," "anticipate," "intend," "expect," "should," "would," "plan," "project," "forecast," "predict," "potential," "seem," "seek," "future," "outlook," "target" or other similar expressions that predict or indicate future events or trends or that are not statements of historical matters. These forward-looking statements include, but are not limited to, statements regarding estimates and forecasts of other financial and performance metrics, projections of market opportunity and market share. These statements are based on various assumptions, whether or not identified in this Presentation, and on the current expectations of LumiraDx's and CAH's management and are not predictions of actual performance. These forward-looking statements are provided for illustrative purposes only and are not intended to serve as, and must not be relied on by any investor as a guarantee, an assurance, a prediction or a definitive statement of fact or probability. Actual events and circumstances are difficult or impossible to predict and may differ from assumptions, and such differences may be material. Many actual events and circumstances are beyond the control of LumiraDx and CAH. These forward-looking statements are subject to a number of risks and uncertainties, including changes in domestic and foreign business, market, financial, political and legal conditions; risks relating to the uncertainty of the projected financial information with respect to LumiraDx; the inability of the parties to successfully or timely consummate the Proposed Business Combination, including the risk that any required regulatory approvals are not obtained, are delayed or are subject to unanticipated conditions that could adversely affect the combined company or the expected benefits of the Proposed Business Combination or that the approval of the stockholders of CAH or LumiraDx is not obtained; the failure to realize the anticipated benefits of the Proposed Business Combination; risks relating to the uncertainty of the projected financial information with respect to LumiraDx; risks related to the rollout of LumiraDx's business and the timing of expected business milestones; the effects of competition on LumiraDx's future business; the amount of redemption requests made by CAH's public stockholders; the ability of CAH or the combined company to issue equity or equity-linked securities or obtain debt financing in connection with the Proposed Business Combination or in the future and those factors discussed in CAH's final prospectus dated January 26, 2021 and any Quarterly Report on Form 10-Q, in each case, under the heading "Risk Factors," and other documents of CAH or LumiraDx filed, or to be filed, with the SEC. If any of these risks materialize or CAH's or LumiraDx's assumptions prove incorrect, actual results could differ materially from the results implied by these forward-looking statements. There may be additional risks that neither CAH nor LumiraDx presently know or that CAH and LumiraDx currently believe are immaterial that could also cause actual results to differ from those contained in the forward-looking statements. In addition, forward-looking statements reflect CAH's and LumiraDx's expectations, plans or forecasts of future events and views as of the date of this Presentation. CAH and LumiraDx anticipate that subsequent events and developments will cause CAH's and LumiraDx's assessments to change. However, while CAH and LumiraDx may elect to update these forward-looking statements at some point in the future, CAH and LumiraDx specifically disclaim any obligation to do so. These forward-looking statements should not be relied upon as representing CAH's and LumiraDx's assessments as of any date subsequent to the date of this Presentation. Accordingly, undue reliance should not be placed upon the forward-looking statements. Neither LumiraDx, CAH, nor any of their respective affiliates have any obligation to update this Presentation.

INDUSTRY AND MARKET DATA

This presentation includes statistical and other industry and market data that we obtained from industry publications and research, surveys and studies conducted by third parties as well as our own estimates of potential market opportunities. Industry publications and third-party research, surveys and studies generally indicate that their information has been obtained from sources believed to be reliable, although they do not guarantee the accuracy or completeness of such information. CAH and LumiraDx believe that these third-party sources and estimates are reliable, but have not independently verified them. LumiraDx's estimates of the potential market opportunities for its Platform include several key assumptions based on industry knowledge, industry publications, third-party research and other surveys, which may be based on a small sample size and may fail to accurately reflect market opportunities. While LumiraDx and CAH believe that their own internal assumptions are reasonable, no independent source has verified such assumptions. The industry in which LumiraDx operates is subject to a high degree of uncertainty and risk due to a variety of important factors that could cause results to differ materially from those expressed in the estimates made by third parties and by LumiraDx or CAH.

USE OF PROJECTIONS

This Presentation contains projected financial information with respect to LumiraDx, including, but not limited to, estimated results for fiscal year 2021. Such projected financial information constitutes forward-looking information, and is for illustrative purposes only and should not be relied upon as necessarily being indicative of future results. The assumptions and estimates underlying such financial forecast information are inherently uncertain and are subject to a wide variety of significant business, economic, competitive and other risks and uncertainties that could cause actual results to differ materially from those contained in the prospective financial information. See "Forward-Looking Statements" paragraph above. Actual results may differ materially from the results contemplated by the financial forecast information contained in this Presentation, and the inclusion of such information in this Presentation should not be regarded as a representation by any person that the results reflected in such forecasts will be achieved. Neither CAH's nor LumiraDx's independent auditors have audited, reviewed, compiled or performed any procedures with respect to the projections for the purpose of their inclusion in this Presentation, and accordingly, neither of them expressed an opinion or provided any other form of assurance with respect thereto for the purpose of this Presentation.

FINANCIAL INFORMATION; NON-GAAP FINANCIAL MEASURES

The financial information and data contained in this Presentation is unaudited and does not conform to Regulation S-X promulgated under the Securities Act. Accordingly, such information and data may not be included in, may be adjusted in or may be presented differently in, any proxy statement/prospectus or registration statement to be filed by CAH with the SEC. Some of the financial information and data contained in this Presentation, have not been prepared in accordance with United States generally accepted accounting principles ("GAAP"). CAH and LumiraDx believe these non-GAAP measures of financial results provide useful information to management and investors regarding certain financial and business trends relating to LumiraDx's financial condition and results of operations. LumiraDx's management uses these non-GAAP measures for trend analyses, for purposes of determining management incentive compensation and for budgeting and planning purposes. CAH and LumiraDx believe that the use of these non-GAAP financial measures provides an additional tool for investors to use in evaluating projected operating results and trends in and in comparing LumiraDx's financial measures with other similar companies, many of which present similar non-GAAP financial measures to investors. The principal limitation of these non-GAAP financial measures is that they are subject to inherent limitations as they reflect the exercise of judgments by management about which expense and income are excluded or included in determining these non-GAAP financial measures.

TRADEMARKS AND TRADE NAMES

LumiraDx and CAH own or have rights to various trademarks, service marks and trade names that they use in connection with the operation of their respective businesses. This Presentation also contains trademarks, service marks and trade names of third parties, which are the property of their respective owners. The use or display of third parties' trademarks, service marks, trade names or products in this Presentation is not intended to, and does not imply, a relationship with LumiraDx or CAH, or an endorsement or sponsorship by or of LumiraDx or CAH. Solely for convenience, the trademarks, service marks and trade names referred to in this Presentation may appear with the ®, TM or SM symbols, but such references are not intended to indicate, in any way, that LumiraDx or CAH will not assert, to the fullest extent under applicable law, their rights or the right of the applicable licensor to these trademarks, service marks and trade names.

CA Healthcare Acquisition Corp. (CAHC) Overview

Lead Transaction Advisor

Tom Cibotti – *CAHC Advisor*

- Managing Member of CAHC Sponsor LLC
- CEO and Managing Director of Covington
- Advised on over 200 transactions including focus of over 20 years in diagnostics

Sponsor Group

COVINGTON ASSOCIATES — *M&A Advisors*

PLEASANT BAY CAPITAL PARTNERS — *Healthcare Focused Private Equity*

SPAC Overview

- CA Healthcare Acquisition Corp. (CAHC) is a NASDAQ listed SPAC which completed its $115MM IPO on January 29th, 2021
- Sponsor group has decades of experience with high-growth healthcare companies

Operationally Led Management Team

Larry Neiterman
Chairman & CEO
Deloitte.
Former COO of Deloitte Global Consulting

Jeff Barnes
President & CFO
PHILIPS
Former CEO of Phillips Canada

Board of Directors

David Lang
Healthcare Private Equity Investor
TA ASSOCIATES

David Klein
Former CEO
The Lifetime Healthcare Companies

Afsaneh Naimollah
Former Head of Technology Investment Banking
BARCLAYS

lumiraDx™

Investment Thesis

CAHC was formed to invest in a high growth healthcare company positioned for long-term success in the public markets

Target Criteria

- Leader in an attractive and growing healthcare market
- Consistent revenue growth of 20%+ YoY
- Capable of operating as a public company
- Interested in partnering with trusted SPAC team with public market currency

LumiraDx Investment Thesis

- ✓ Strong relationship with a management team with a long-term track record of success
- ✓ Large market opportunity improving care pathways and outcomes at the point of care
- ✓ Platform validation and global revenue acceleration with blue-chip customers, including CVS, NHS, and The Gates Foundation
- ✓ Robust assay pipeline
- ✓ Well positioned for long-term shareholder value creation

LumiraDx's Proven Track Record

Ron Zwanziger
CEO, Co-Founder, Chairman and Director

Dave Scott, Ph.D.
Chief Technology Officer, Co-Founder and Director

Jerry McAleer, Ph.D.
Chief Scientist, Co-Founder and Director

David Walton, D.M.S.
Chief Commercial Officer

Nigel Lindner, Ph.D.
Chief Innovation Officer

Veronique Ameye
Executive Vice President and General Counsel

Tom Quinlan
General Manager, Health IT

Dorian LeBlanc, C.P.A.
CFO and Vice President, Global Operations

Peter Scheu
President, North American Commercial Operations

Pooja Pathak
Vice President, Platform Strategy

lumiraDx™

Founded in 2014

ALERE

Sold to Abbott for $8.2B

INVERNESS

Sold to J&J for $1.3B



MEDISENSE

Sold to Abbott for $900M

lumiraDx™

Our Mission

We are focused on transforming community-based healthcare by providing fast, accurate and comprehensive diagnostic information to healthcare providers at the point of need, thereby enabling better medical decisions leading to improved outcomes at lower cost.

Our diagnostic solutions are designed to be affordable and accessible for every individual around the world.

Current Point of Care (POC) Solutions Have Major Limitations

The traditional approach to POC test development has limited scalability and has resulted in ineffective, inefficient and costly solutions

TNI, CK-MB, Myoglobin, BNP, D-Dimer, TOX

Flu A/B, RSV, Strep

Flu A/B, RSV, Strep

Lipid Profile, Glucose

INR

HbA1c, CRP, ACR

- **Poor clinical performance in areas of high clinical need**
- **Limited test menu**
- **High cost of total ownership**

lumiraDx™

Healthcare Providers Need Solutions to Combat the Proliferation of Instruments at the POC

Typical Physician Office Lab





We Have Developed and Commercialized an Innovative, Disruptive Solution for POC Testing

Consolidating multiple POC systems onto a single instrument, The LumiraDx Platform is designed to be a one-stop solution to transform diagnostic testing and health outcomes around the world



- **Lab-comparable performance in minutes**
- **Broad menu of tests on a single instrument**
- **Low cost of ownership**

lumiraDx™

Comprehensive COVID-19 Portfolio

COVID-19 accelerated the go-to-market strategy for technology that LumiraDx has been developing for years

RNA STAR	Antigen/Antibody	Antigen Pool	Antigen
Open Molecular Systems	LumiraDx Platform	LumiraDx Platform	*Amira System

Reference Labs

POC Labs

Professional-Led Screening

Home / Consumer Venues

Decentralization

Partnering with governments, health systems, retail chains, enterprises and global foundations to deploy next-generation testing across healthcare, community, workplace and home settings.

Note: LumiraDx SARS-CoV-2 Antibody and LumiraDx SARS-CoV-2 Antigen Pool are available under CE Mark only; not available in the US
*The Amira System is in development and is subject to regulatory approval, authorization or clearance.

Multiple Testing Solutions Beyond COVID to Improve Performance, Speed and Cost from Lab to Home



Note 1: 2021 Global Total Addressable Market: Company estimates only include products on market and in development
Note 2: Lab Solutions and Amira TAM includes COVID-19 only; Platform TAM includes POC COVID and other products on market and in development

Global Sales and Channel Partnership Strategy

Establish Partnerships → **Create Panels that Address Market Needs** → **Rollout Relevant Menu to Partner Sites "Expand"** → **Further Expand Menu at Partner Sites "Exponentially Expand"**

Retail Pharmacies and Clinics	***Healthcare Systems and Government Organizations***	***Global Health Foundations***
CVS pharmacy, Boots	*United Kingdom's Healthcare System* NHS; *Italy's Healthcare System*	Bill & Melinda Gates foundation
Consumers and Employers	*Hospitals and Community Physician Practices*	*Africa and Developing Countries*

For the Amira System, LumiraDx plans to pursue a B2C over-the-counter rollout strategy to drive commercial adoption for mass "at-home" screening

Addressing The Most Common Conditions

Robust pipeline of test rollouts over the next twelve months

Test	Status	Area	Regulatory Cleared Markets	12 Month Regulatory Submissions or Certifications [1]
COVID-19 antigen	Regulatory Cleared	Infectious Disease	US (EUA), Europe, Japan, Latin America	-
COVID-19 antibody	Regulatory Cleared	Infectious Disease	Europe	US, Japan, Africa
COVID-19 pool	Regulatory Cleared	Infectious Disease	Europe	US (EUA), Africa
INR	Regulatory Cleared	Coagulation Disorders	Europe	US, Latin America
D-Dimer	Regulatory Cleared	Coagulation Disorders / Cardiovascular Disease	Europe	US
Flu A/B + COVID-19 antigen	In Development	Infectious Disease	–	US (EUA), Japan, Europe, Africa
CRP	In Development	Infectious Disease	–	Europe, Japan, Africa
HbA1c	In Development	Diabetes	–	US, Europe
Flu A/B + RSV	In Development	Infectious Disease	–	US, Europe
High Sensitivity Troponin I	In Development	Cardiovascular Disease	–	US, Europe
HIV Molecular	In Development	Infectious Disease	–	–[2]
COVID-19 antigen - Amira	In Development	Infectious Disease	–	Africa, US, Europe [3]

(1) We expect to submit a request for regulatory approval, authorization, clearance or self-certify, as applicable, in the next 12 months in the markets listed for each test
(2) We plan to submit a prequalification submission to the World Health Organization in next 12 months
(3) We expect to submit a request for regulatory approval, authorization, clearance or self-certify, as applicable, in the fall of 2021 in the markets listed for the test

lumiraDx™

Key Metrics Snapshot

>$1B

Total Capital Raised

Annual Revenue ($M)



$334M

Estimated Cash Balance as of 3/31/21

1K+

Platform Instruments Manufactured per Week

>13K

Platform Instruments Shipped Since Sept 20'

15M+

Platform Test Manufacturing Capacity per Month

7

Regulatory Cleared Tests*

30+

# of Tests in Pipeline

60+

# of Countries with Instrument Placements

*Includes 5 platform and 2 laboratory approved tests

LumiraDx Platform

Transforming Community-Based Healthcare

Large and Underpenetrated Testing Market

Accelerated near-term market growth due to COVID-19

Global Diagnostics Testing Market (incl. COVID-19)



Represents a ~$76B growth opportunity for LumiraDx's POC testing to take testing volume share

Testing Prices



POC's limited market share is due to limited menu of expensive tests. LumiraDx sees a significant opportunity to expand POC market share with broader test menu and performance similar to central laboratory with lower prices at POC.

Note: Global Diagnostics Testing Market and Testing Prices based on company estimates and exclude the mass screening market which we intend to target with our Amira System, assuming completion of development and regulatory approval.

Simplifies, Scales Down and Integrates Principles Used in Lab Systems

	LumiraDx Platform	Central Lab System
Common Transduction	Fluorescence / electrochemical	Fluorescence / chemiluminescence
Precise Fluidic Control	Piezo bender / test strip bladder	Syringe pumps
No Sample Matrix Bias	Gas wash / liquid-free image	Multiple buffer washes
Non-Specific Binding Control	Particle coating / anti-hama	Assay design / anti-hama
Calibration Bias	Calibration to lab standard	Calibration to lab standard
Assay Precision	Materials, process, assay controls	Chemistry, assay controls

lumiraDx™

Next Gen, Microfluidic Immunofluorescence Technology Drives High Sensitivity At Point Of Care



Smart Connectivity

- Digital instructions
- Automatic display of results and reporting
- Data analytics and decision support
- Seamless, secure digital connectivity to the cloud and hospital IT systems

COVID-19 Antigen — LumiraDx Platform

POC Competitive Landscape

	LumiraDx Ag	Quidel Sofia (1)	BD Veritor (1)	Abbott BinaxNOW (1)
Technology	Microfluidic Test Strip with Instrument	Lateral Flow with Reader	Lateral Flow with Reader	Lateral Flow
COV-2 Sensitivity	**97.6%**	96.7%	84.0%	84.6%
Confidence Interval	**91.6 – 99.3%**	83.3 – 99.4%	67.0 – 93.0%	76.8 – 90.6%
Intended Use Days Post Symptoms	**12**	5	5	7
Data Set	Nasal Swab – 83	Nasal Swab – 30	Nasal Swab – 31	Nasal Swab – 117
LOD	**$TCID_{50}$ per mL Direct – 32**	$TCID_{50}$ per mL Direct – 113	$TCID_{50}$ per mL Direct – 140	$TCID_{50}$ per mL Direct – 141
COV-2 Specificity	96.6%	100%	100%	98.5%
Time-to-Results	**12 Minutes**	15 Minutes	15 Minutes	15 Minutes
Sample Types	Nasal	Nasal, NP	Nasal	Nasal

Fastest, most sensitive antigen POC test currently commercially available

(1) Tests included represent some COVID-19 antigen tests that have received EUA.
Sources: Product inserts and Emergency Use Authorization documentation for such products.

High Sensitivity Up to Ct<33 Enables Fast, Accurate Detection of Infective Individuals



Source: Adapted from La Scola, B. et al. Eur J Clin Microbiol Infect Dis. 2020; 39(6):1059–1061

The Incremental Sensitivity Has Public Health Impact

- ~50% of COVID-19 patients measure Ct>25 and 30% measure Ct>30 on PCR and are potentially missed by antigen lateral flow tests[1]
- LumiraDx COVID-19 antigen test demonstrates high sensitivity at Ct<33
  - **100% sensitivity at CT<33 in clinical studies**
  - **97.6% overall positive agreement with PCR for samples collected within 12 days from symptom onset (DSO)**
  - **12 DSO is almost 2 times greater than any other antigen test**
- LumiraDx COVID-19 antigen test can detect 10-30%* of incremental cases, high coverage of all infective individuals

*Based on company estimate

(1) Ct values differ by platform, and the distribution varies by population; these are some estimates based on literature.

Broader Diagnostic Portfolio — LumiraDx Platform

	Large Existing Dx Testing Volumes		
Testing Categories	Large, **Concentrated POC** Testing Categories with **Further Growth Potential**	Large, **Fragmented POC** Testing Categories with **Further Growth Potential**	**Small POC Testing** Categories with **Large Potential**
Examples	◉ INR ◉ HbA1c ◉ CRP	◉ Flu A/B + RSV ◉ Flu A/B + COVID-19	◉ High Sensitivity Troponin I ◉ D-Dimer ◉ HIV Molecular
Our Approach	◉ Deliver benchmark POC performance ◉ Offer product at discounted price ◉ Offer key companion tests ◉ Grow POC testing market	◉ Combine high clinical performance with competitive price ◉ Differentiate with single platform approach and companion testing	◉ Develop lab comparable performance test ◉ Offer at small premium to lab prices ◉ Ensure POC usability ◉ Drive volumes to POC

lumiraDx™

Amira System

Mass Screening and Home Testing System for COVID-19



System comprises:

- A small, battery operated, disposable device
- The Amira COVID-19 test kit
- A phone/tablet application for test management & reporting

Submitted pre-EUA request to FDA in March 2021 and plan to obtain CE Mark for POC and over-the-counter applications in the fall of 2021.

Further opportunities in screening and home testing.

lumiraDx™

Large Preventative COVID-19 Testing Opportunity

Diagnostic Testing of High-Risk Subjects

- Symptomatic patient testing
- Rapid testing of high-risk groups (e.g., nursing homes, healthcare workers)



Screening of Socializing Populations

- Screening at public events, airports, schools and workplaces
- 45 – 55% of total population
- 20 – 30% tested 2-3 times per month

Regular, Preventative Testing of General Population

- Screening at schools, universities and workplaces
- 45 – 55% of total population
- 80 – 100% tested 1-3 times per week

$5–15 Billion Market with Significant Expansion Potential(1)

(1) Based on company estimates
Note: Metrics based on company estimates

Amira – High Sensitivity Mass Testing Solution

Amira is addressing the $5-15B decentralizing mass COVID-19 market opportunity(1)

Price Per Test



Anticipated Daily Production



Note 1: Daily production for Lucira, Ellume, and Abbott are current estimates based on certain publicly made statements and LumiraDx's is anticipated production capacity by the fall of 2021.

(1) Company estimate

(2) Anticipated price

Lab Solutions

Fast Lab Solutions Value Proposition

Fast Lab Solution utilizes LumiraDx's innovative qSTAR molecular amplification technology in an accessible high-throughput format to leverage current molecular laboratory operations which improves efficiency and speed

Efficiency
Increase testing capacity 2-5x over common molecular system

Speed
Rapid amplification time in minutes not hours

Accessible
Leverages common high throughput platforms

Menu
Potential opportunities in respiratory and infectious diseases inc. panels

lumiraDx™

Fast Lab RNA STAR – COVID-19 Product Overview

	LumiraDx SARS CoV-2 RNA STAR EUA Authorized	**LumiraDx SARS CoV-2 RNA STAR Complete** EUA Authorized
Sample Types	Nasopharyngeal, Nasal, Oropharyngeal	Nasopharyngeal, Nasal, Oropharyngeal [RUO saliva available]
Sample Collection	Swab in Viral Transport Media (VTM)	Direct swab or VTM (1 mL) [RUO saliva available]
Limit of Detection (LoD)	0.5 copy/uL	1.8 copy/uL
Upfront Workflow (approx.)	Dependent on Extraction Method Approximately 2-2.5 hours	10-minute Master Mix prep
Time to Result	12-minute amplification	20-minute amplification
Extraction Systems	QIAsymphony, MagMAX Viral/Pathogen II, QIAamp Viral RNA Mini Kit	N/A
Thermocyclers	ABI 7500 Fast Dx, QuantStudio, Agilent AriaMx, LightCycler 480ii, Agilent Mx3005P	ABI 7500 Fast Dx, QuantStudio (5, 7 Flex & 7 Pro), Agilent AriaMx, LightCycler 480ii, Biorad CFX-96 Agilent Mx3005P

Commercial

Global Commercial Footprint

Commercial Overview

- >1,200 employees, of which 131 are commercial employees (as of 3/31/21) located in 17 countries
- Direct sales and marketing operations in the US, most Western European countries, Japan, South Africa, Colombia and Brazil
- Over time, plan to:
  - Operate with a direct commercial presence in each of the largest diagnostics markets, including China, India and Southeast Asia
  - Collaborate with distribution partners and medical wholesalers to ensure broad access globally

Commercial Status

- As of 3/31/21, shipped 13,000+ LumiraDx Platform Instruments with 800+ customers across 60+ countries

Instrument Placement Locations

LumiraDx™

Large Scale Manufacturing Infrastructure Enabling Global Growth

	Instruments	Test Strips
LumiraDx Platform	• Manufactured by Flextronics in Althofen, Austria	• Manufactured on a common platform using a high volume, web-based, automated process • Capacity of 15M+ test strips per month in January 2021 and 35-45M test strips per month by mid-2021 • Located in Scotland and U.S. (strips and components)
Amira System	• Manufactured in US/planned Mexico	• Manufactured in similar fashion to platform test strips • Expected capacity of 10M test strips per day by the fall of 2021 • Located in England

Protected by Extensive IP Portfolio

- Ring-fence model with multi-layer protection approach
- Significant and growing patent estate relating to our Platform technologies, clinical assays, Amira System and related technologies
  - At least 10 US patents, 7 pending US non-provisional patent applications, 7 pending US provisional applications
  - At least 60 foreign patents, 60 pending foreign patent applications, and 4 pending PCT patent applications
- Strong focus on protection of confidential know-how and trade secrets



Note: Data as of March 31, 2021.

Summary Investment Highlights

1. **Disruptive solutions for Point Of Care “POC” and mass testing**
2. **Superior performance and expansive test menu at competitive cost**
3. **Successful manufacturing scale-up enabling global growth strategy**
4. **Significant revenue ramp from major strategic and government partners**
5. **Pipeline of 30+ diagnostic tests to drive platform utilization from large installed base**

lumiraDx™

Financial Overview

Recent Operating Results

($ stated in Thousands)

	Three Months Ended December 31, 2020	Year Ended December 31, 2020
Revenue	**$112,274**	**$139,153**
Operating Income/(Loss)	$2,824	(100,721)
Net Loss[1]	(71,062)	(240,997)

(1) Net Losses include $71,341 and $138,479 of net non-cash finance expenses in 4Q20 and full-year 2020 respectively

Pro-Forma Terms of the Transaction (Based on 3/31)

(Stated in Millions other than per share and percentage metrics)

Pro Forma Ownership



Key Points

- No existing LumiraDx shareholders will be selling shares
- The additional capital and new financing commitments and cash from operations will provide growth capital to support increasing product demand, continued R&D activities and commercial and manufacturing expansion.
- The transaction is currently expected to close by the end of the second quarter/beginning of the third quarter of 2021.

Sources and Uses

Sources	
LumiraDx Equity	$5,000
CAHC Cash Held in Trust[1]	$115
Total Sources	**$5,115**
Uses	
LumiraDx Equity	$5,000
Cash to LumiraDx Balance Sheet	$99
Estimated Combined Fees & Expenses	$16
Total Uses	**$5,115**

Pro Forma Valuation

Shares Outstanding	515
Price Per Share	$10.00
Market Capitalization	$5,148
Less Cash Balance[2]	$(433)
Plus Debt[3]	$318
Enterprise Value	**$5,033**

(1) Assumes no redemptions
(2) Assumes company cash balance as of 3/31/2021 of $334M plus $115M from cash in trust minus $16M of estimated combined fees & expenses
(3) Includes $300M of BioPharma Credit debt, $18M The Gates Foundation debt, and excludes convertible debt that will be converted as a part of the transaction
Note 1: Numbers presented are pro forma, estimated as of 3/31/2021, and exclude any funding from Capital One
Note 2: Excludes 5.75M public warrants